Field report E-51 / N8 · sheet /strategy

Corporate StrategyFiled from the territory

Altria CEO Calls FDA Rules 'Broken' as Lawsuit Pauses

Altria CEO Sal Mancuso says FDA reviews meant to take 180 days stretch to six years, and the company's lawsuit against the regulator is now paused as the agency weighs reform.

Grid
E-51 / N8
Surveyed
November 18, 2026
Reading
3 min read
Correspondent
Elena Vasquez
Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it su
Fig. E-51 / N8Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it su — NoblePrime / pixabay

Field notes

  1. Altria sued the FDA in September over delays in the 180-day Premarket Tobacco Product Application review process.
  2. CEO Sal Mancuso said some product reviews have taken six years instead of the statutory six months.
  3. A federal judge paused the litigation last month while the FDA considers PMTA revisions.
  4. Altria launched its Moving Beyond Smoking smoke-free strategy in 2023, including On! pouches and NJOY vapes.
  5. Mancuso aims to overtake Philip Morris's Zyn and lead the nicotine pouch category long term.

Altria CEO Sal Mancuso has branded U.S. nicotine product regulation "broken," saying reviews that legally must finish within 180 days are stretching to six years while unregulated foreign products flood store shelves.

Speaking at the Fortune 500 Innovation Forum in Detroit on Monday, the head of the Marlboro and Black & Mild owner said the Food and Drug Administration's review process has stalled newer versions of its On! nicotine pouches — a product line central to the company's smoke-free strategy.

"Quite frankly, the regulations are broken," Mancuso told Fortune Executive Editorial Director Diane Brady. "There's too much information. We still want a high standard, but it should be streamlined."

Why did Altria sue the FDA?

Altria, through subsidiaries Helix Innovations and NJOY, sued the FDA in September. The suit claims the agency blocked newer nicotine products from reaching the market through its Premarket Tobacco Product Application process.

Under the PMTA framework, the FDA must review new tobacco products and decide whether each provides an overall public health benefit within 180 days of an application. Altria alleges the regulator routinely misses that deadline — by years, not weeks. Mancuso said what should take six months was taking six years in some cases.

The company argues the delay has consequences beyond lost sales. Illegal products, particularly from China, are not only capturing market share but also sidestepping safety standards Mancuso believes the FDA should enforce to protect consumers. He claimed some competing overseas products are marketed in vape shops as American-made, but are mislabeled.

The litigation is now on hold. Last month, U.S. District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause the case. The FDA said it would consider revisions to the PMTA and new rules as the market changes.

What is the 'Moving Beyond Smoking' strategy?

Altria launched its Moving Beyond Smoking initiative in 2023 as consumers shift away from cigarettes. The strategy centers on smoke-free alternatives, including NJOY vapes and On! nicotine pouches, which compete directly with Philip Morris's market-leading Zyn brand.

Mancuso conceded Altria's current position in pouches is weak but set a long-term target to overtake its rival.

"You can call us the underdog in the pouch category today, but our intention is to lead the pouch category over the long term," he said.

He identified two obstacles to that goal. First, a public misperception: consumers wrongly believe nicotine itself causes the harm from tobacco use, when most of the damage comes from combustion. Second, the FDA regulatory burden itself.

"When you're in the nicotine business, responsibility needs to be at the heart of everything you do," Mancuso said.

What does Altria want from regulators?

Mancuso's central demand is speed with standards intact. He distinguished between formal rules and informal agency guidance, arguing only durable regulation gives companies certainty.

"Guidance is not durable," he said. "It can be torn up immediately. What we want is more rapid authorization, so that consumers have product choices that they can choose from."

He drew a comparison to cannabis, which is legal in roughly half of U.S. states yet has no federal standard — a "hodgepodge" of rules in his words.

"Regulations are hard for any business," Mancuso said. "At the very least, it should be an even playing field, not a playing field where bad actors are in a better position than responsible companies like ours."

via fortune.com/feed/ (Source)

Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.

489 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetE-51 / N8 · November 18, 2026